Home › NDC Lookup › RxCUI directory › RxCUI 616749

12 HR ranolazine 500 MG Extended Release Oral Tablet — RxCUI 616749

RxNorm drug concept · Semantic clinical drug
RxCUI 616749 Semantic clinical drug · SCD ● Current RxNorm concept 54 FDA products 110 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI616749
Official name12 HR ranolazine 500 MG Extended Release Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asranolazine 500 MG 12HR Extended Release Oral Tablet
FDA products mapped54
Package NDCs mapped110
Reported Medicaid activity (SDUD)134,697 prescriptions · 51 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Ranolazine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Ranolazine is specifically for chronic angina — the recurring chest pain or tightness you get when your heart isn't getting enough blood flow. It's not a heart attack treatment or...
  • What exactly is ranolazine supposed to do for me?
  • If you're taking the extended-release tablet (Ranexa or generic ranolazine), you can take it with or without food — your choice. The important thing is to swallow it whole. Never c...
  • Do I have to take this with food? And can I split the tablet?
📖 Read our full Ranolazine guide →

🕸️ Concept Web — How 12 HR ranolazine 500 MG Extended Release Oral Ta... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 12 HR ranolazine 500 MG Extended Release Oral Tablet RxCUI 616749

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Ranolazine 35829
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Ranexa 356778
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Ranolazine Extended Release Oral Tablet 616491
    • Ranolazine Oral Product 1157902
    • Ranolazine Pill 1157903
    • Ranolazine Extended Release Oral Tablet [Ranexa] 616494
    • Ranexa Oral Product 1177693
    • Ranexa Pill 1177694
    • Extended Release Oral Tablet 316945
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Ranolazine 500 MG 616490
    • 12 HR ranolazine 500 MG Extended Release Oral Tablet [Ranexa] 860738
    • Ranolazine 500 MG [Ranexa] 616493

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Ranolazine 500 MG SCDC · 616490
  • Ranolazine Extended Release Oral Tablet SCDF · 616491
  • Ranolazine Oral Product SCDG · 1157902
  • Ranolazine Pill SCDG · 1157903

Brand-Name Concepts

  • 12 HR ranolazine 500 MG Extended Release Oral Tablet [Ranexa] SBD · 860738
  • Ranolazine 500 MG [Ranexa] SBDC · 616493
  • Ranolazine Extended Release Oral Tablet [Ranexa] SBDF · 616494
  • Ranexa Oral Product SBDG · 1177693
  • Ranexa Pill SBDG · 1177694
  • Ranexa BN · 356778

📦 FDA Products & Package NDCs

54 products · 110 package NDCs
110 package NDCs map to RxCUI 616749 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
72578-0065-05 500 TABLET, EXTENDED RELEASE in 1 BOTTLE (72578-065-05) Ranolazine Viona Pharmaceuticals Inc 2019-09-10
72578-0065-14 60 TABLET, EXTENDED RELEASE in 1 BOTTLE (72578-065-14) Ranolazine Viona Pharmaceuticals Inc 2019-09-10
72578-0065-77 10 BLISTER PACK in 1 CARTON (72578-065-77) / 10 TABLET, EXT... Ranolazine Viona Pharmaceuticals Inc 2019-09-10
73141-0021-02 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTI... RANOLAZINE A2A Integrated Pharmaceuticals 2025-04-08
73141-0022-02 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTI... RANOLAZINE A2A Integrated Pharmaceuticals 2025-04-08
77771-0423-60 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 PACKAGE (77771... RANOLAZINE Radha Pharmaceuticals, Inc 2025-06-30
77771-0424-60 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 PACKAGE (77771... RANOLAZINE Radha Pharmaceuticals, Inc 2025-06-30
82804-0118-60 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (82804-... Ranolazine Proficient Rx LP 2024-07-05
90096-0151-60 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (90096-... Ranolazine Zameer Pharmaceuticals LLC 2026-04-22
90096-0152-60 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (90096-... Ranolazine Zameer Pharmaceuticals LLC 2026-04-22
Observed labelers: Proficient Rx LP (15) · Viona Pharmaceuticals Inc (8) · Zydus Lifesciences Limited (8) · Micro Labs Limited (7) · Ascend Laboratories, LLC (6) · Aurobindo Pharma Limited (6) · +22 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.